Sugi Predict

Sugi Predict / Compounds / Hydrochloric Acid

Hydrochloric Acid

Hydrochloric Acid

SCHEMBL439397

Cl.O=C(NC1CCNCC1)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 known ✓ P08172 1/20 0.41
▸ CHRM1 known ✓ P11229 1/20 0.41
▸ CHRM3 known ✓ P20309 1/20 0.41
▸ HDAC4 known ✓ P56524 1/20 0.38
▸ HDAC6 known ✓ Q9UBN7 1/20 0.38
▸ GABRP known ✓ O00591 1/20 0.35
▸ GABRD known ✓ O14764 1/20 0.35
▸ GABRA1 known ✓ P14867 1/20 0.35
▸ GABRB1 known ✓ P18505 1/20 0.35
▸ GABRG2 known ✓ P18507 1/20 0.35
▸ GABRB3 known ✓ P28472 1/20 0.35
▸ GABRA5 known ✓ P31644 1/20 0.35
▸ GABRA3 known ✓ P34903 1/20 0.35
▸ GABRA2 known ✓ P47869 1/20 0.35
▸ GABRB2 known ✓ P47870 1/20 0.35
▸ GABRA4 known ✓ P48169 1/20 0.35
▸ GABRE known ✓ P78334 1/20 0.35
▸ GABRA6 known ✓ Q16445 1/20 0.35
▸ GABRG1 known ✓ Q8N1C3 1/20 0.35
▸ GABRG3 known ✓ Q99928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4374405 0.98 EPHX1 (0.59) EPHX1POLBPKMPDK1PDK2
SCHEMBL2517789 0.91 EPHX1 (0.55) EPHX1POLBPKMPDK1PDK2
SCHEMBL2519751 0.91 EPHX1 (0.55) EPHX1POLBPKMPDK1PDK2
SCHEMBL2518911 0.91 EPHX1 (0.55) EPHX1POLBPKMPDK1PDK2
Hydrochloric Acid SCHEMBL1878764 0.89 EPHX1 (0.44) EPHX1POLBPKMPDK1PDK2
Hydrochloric Acid SCHEMBL1027224 0.89 EPHX1 (0.44) EPHX1POLBPKMPDK1PDK2
Hydrochloric Acid SCHEMBL1873541 0.89 EPHX1 (0.44) EPHX1POLBPKMPDK1PDK2
SCHEMBL1029383 0.86 EPHX1 (0.45) EPHX1POLBPKMPDK1PDK2
SCHEMBL3405244 0.86 EPHX1 (0.45) EPHX1POLBPKMPDK1PDK2
SCHEMBL3402629 0.86 EPHX1 (0.45) EPHX1POLBPKMPDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11732259-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2023-08-22 — — US disclosed
US-11225662-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2022-01-18 — — US disclosed
US-20210283170-A1 METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS SAREPTA THERAPEUTICS INC (US) 2021-09-16 — — US disclosed
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. 2021-05-13 — — US disclosed
US-20210139896-A1 Peptide Oligonucleotide Conjugates JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2021-05-13 — — US disclosed
US-20200277598-A1 Peptide Oligonucleotide Conjugates JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-09-03 — — US disclosed
US-10760078-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2020-09-01 — — US disclosed
US-20190218551-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
CN-103003288-B Oligonucleotide analogues with modified intersubunit linkages and/or terminal groups 萨勒普塔医疗公司 2019-06-21 — — CN disclosed
US-10202602-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2019-02-12 — — US disclosed
CN-107353317-A The oligonucleotide analogs of key and/or end group between subunit with modification 萨勒普塔医疗公司 2017-11-17 — — CN disclosed
CN-103619356-B Peptide oligonucleotide conjugates 萨勒普塔医疗公司 2017-09-12 — — CN disclosed
US-20170198287-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2017-07-13 — — US disclosed
US-9469664-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2016-10-18 — — US disclosed
US-20160237426-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2016-08-18 — — US disclosed
US-9161948-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2015-10-20 — — US disclosed
US-20150073140-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. (US) 2015-03-12 — — US disclosed
US-8779128-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2014-07-15 — — US disclosed
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES AVI BIOPHARMA, INC. (US) 2012-11-15 — — US disclosed
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2012-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218551-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB CHRM2 4832/4885CHRM1 4843/4885CHRM3 4679/4885
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB CHRM2 4832/4885CHRM1 4843/4885CHRM3 4679/4885
US-20200277598-A1 Peptide Oligonucleotide Conjugates SNRPE, SMN1; SMN2, UPF1 CHRM2 4771/4885CHRM1 4817/4885CHRM3 4738/4885
US-10202602-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups NSUN2, RTCB, UPF1 CHRM2 4830/4885CHRM1 4842/4885CHRM3 4677/4885
US-10760078-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups NSUN2, UPF1, RTCB CHRM2 4832/4885CHRM1 4843/4885CHRM3 4679/4885
US-20210139896-A1 Peptide Oligonucleotide Conjugates SNRPE, SMN1; SMN2, UPF1 CHRM2 4771/4885CHRM1 4817/4885CHRM3 4738/4885
US-20150073140-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB CHRM2 4832/4885CHRM1 4843/4885CHRM3 4679/4885
US-20210283170-A1 METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS HLA-DRB1, CD4, MALT1 CHRM2 2316/4885CHRM1 1730/4885CHRM3 2307/4885
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB CHRM2 4832/4885CHRM1 4843/4885CHRM3 4679/4885
US-20160237426-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES SNRPE, SMN1; SMN2, UPF1 CHRM2 4771/4885CHRM1 4817/4885CHRM3 4738/4885
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES SNRPE, SMN1; SMN2, UPF1 CHRM2 4771/4885CHRM1 4817/4885CHRM3 4738/4885
US-11225662-B2 Peptide oligonucleotide conjugates SNRPE, SMN1; SMN2, UPF1 CHRM2 4771/4885CHRM1 4817/4885CHRM3 4738/4885
US-11732259-B2 Peptide oligonucleotide conjugates SNRPE, SMN1; SMN2, UPF1 CHRM2 4771/4885CHRM1 4817/4885CHRM3 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.